Statement: Less patients in cohort 2 of the primary trial had an unusual amount of fluid around the lungs than in cohort 1.
Primary_evidence: Adverse Events 1:   Total: 1/24 (4.17%)   Pericardial effusion *1/24 (4.17%)   Other cardiac disorder *0/24 (0.00%)   Ejection fraction decrease *0/24 (0.00%)   Hypertension *0/24 (0.00%)   Salivary gland infection *0/24 (0.00%)   Pleural effusion *0/24 (0.00%) Adverse Events 2:   Total: 6/30 (20.00%)   Pericardial effusion *1/30 (3.33%)   Other cardiac disorder *1/30 (3.33%)   Ejection fraction decrease *1/30 (3.33%)   Hypertension *1/30 (3.33%)   Salivary gland infection *1/30 (3.33%)   Pleural effusion *2/30 (6.67%)